Department of Pharmaceutical Microbiology, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Animal, Plant and Food Inspection Center of Nanjing Customs, Nanjing, China.
J Appl Microbiol. 2022 Sep;133(3):1392-1401. doi: 10.1111/jam.15643. Epub 2022 Jun 7.
Lactobacillus species are the dominant microorganisms in the vaginal microbiota of healthy women and play an important role in the defence against pathogens. This study aimed to evaluate probiotic potential of Lactiplantibacillus plantarum strain P1 isolated from healthy woman's vaginal discharge for its further utilization as a promising candidate strain in the treatment of bacterial vaginosis caused by Gardnerella vaginalis.
Ten lactobacilli strains from a woman's vaginal discharge were evaluated for their probiotic potential, including growth capacity at different pH levels (pH 3.5-4.5), acid production, hydrogen peroxide production capacity, antibacterial activity and susceptibility to antibiotics. Moreover, in vitro safety assay haemolytic activity and mutagenicity were investigated for safety assessment. In vivo Caenorhabditis elegans infection model was used to investigate the anti-infection effect of selected isolates. We found that lactobacilli strain P1 showed strong growth ability in low acid environment, produced acid, hydrogen peroxide, had the strongest antibacterial activity against G. vaginalis and was highly susceptible to the tested antibiotics. When assayed for the safety, strain P1 showed no haemolytic activity and had no effect of mutagenicity. Moreover, P1 significantly increased the lifespan of C. elegans against G. vaginalis infection. Combined with the results of 16S rRNA gene sequencing, morphological and physiological characteristic, the strain was identified as Lactiplantibacillus plantarum.
Lactiplantibacillus plantarum strain P1 proves to be a promising candidate strain in the treatment of bacterial vaginosis caused by G. vaginalis.
Conventional antibiotic therapy for bacterial vaginosis has led to the accelerated process of bacterial drug resistance. Probiotics are potentially an alternative method for bacterial vaginosis therapy. This finding provides bacterial resources for keeping pathogens away from the vagina. We believe L. plantarum P1 may be used as vaginal probiotics and be useful to prevent or treat bacterial vaginitis.
乳杆菌属是健康女性阴道微生物群的主要微生物,在防御病原体方面发挥着重要作用。本研究旨在评估从健康女性阴道分泌物中分离出的植物乳杆菌 P1 菌株的益生菌潜力,因为其有望成为治疗由阴道加德纳菌引起的细菌性阴道病的候选菌株。
评估了来自女性阴道分泌物的 10 株乳杆菌菌株的益生菌潜力,包括在不同 pH 值(pH 3.5-4.5)下的生长能力、产酸、产过氧化氢能力、抗菌活性和对抗生素的敏感性。此外,还研究了体外安全性试验的溶血活性和致突变性,以进行安全性评估。使用体外 Caenorhabditis elegans 感染模型来研究所选分离物的抗感染效果。我们发现,乳杆菌 P1 菌株在低酸环境中具有很强的生长能力,产生酸、过氧化氢,对阴道加德纳菌的抗菌活性最强,且对测试的抗生素高度敏感。在安全性检测中,P1 菌株没有溶血活性,也没有致突变作用。此外,P1 菌株显著延长了 C. elegans 对 G. vaginalis 感染的寿命。结合 16S rRNA 基因测序、形态和生理特征的结果,该菌株被鉴定为植物乳杆菌。
植物乳杆菌 P1 菌株有望成为治疗阴道加德纳菌引起的细菌性阴道病的候选菌株。
传统的细菌性阴道病抗生素治疗导致了细菌耐药性的加速发展。益生菌可能是细菌性阴道病治疗的一种替代方法。这一发现为阴道病原体防治提供了细菌资源。我们相信 L. plantarum P1 可以用作阴道益生菌,有助于预防或治疗细菌性阴道炎。